Buyukbayram Mehmet Emin, Hannarici Zekeriya, Duzkopru Yakup, Turhan Aykut, Caglar Alperen Akansel, Coban Esdur Pınar, Bilici Mehmet, Tekin Salim Basol, Yazılıtaş Doğan
Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey.
Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
Breast Cancer (Dove Med Press). 2024 Jul 3;16:329-339. doi: 10.2147/BCTT.S464161. eCollection 2024.
Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.
This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.
Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).
In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.
激素阳性乳腺癌是一种死亡率较高的肿瘤。抗激素疗法与细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）联合使用可延长生存期。炎症参数如C反应蛋白和C反应蛋白/淋巴细胞比值（CLR）对CDK4/6i治疗疗效和生存期的影响尚不清楚。在我们的研究中，我们旨在探讨CLR和一些参数在预测CDK4/6i治疗无进展生存期（PFS）中的作用。
这项回顾性队列研究纳入了78例接受CDK4/6i治疗的初发和复发性转移性乳腺癌患者。通过ROC曲线分析确定各种数值参数评分预测死亡率的临界值。采用Kaplan-Meier法分析临床变量、炎症和组织病理学参数对生存期的影响。
中性粒细胞/淋巴细胞比值（NLR）和CLR在预测死亡率方面具有统计学意义（p<0.05）。Ki67和CLR与PFS相关。年龄和CLR与总生存期（OS）相关（p<0.05）。CLR对PFS（p=0.022）和OS（p=0.006）均具有统计学意义。
在使用CDK4/6i的转移性激素阳性乳腺癌患者中，低CLR和低Ki67与更长的PFS持续时间相关。
